UCSD Will Blend Novel PGx Program With Its Medicine, Pharmacy Schools | GenomeWeb

When it comes to bringing pharmacogenomics to the mainstream, three heads may be better than one. Or at least that’s what the state of California and the National Institutes of Health are betting on.

Recently, the University of California, San Diego, collected $7.5 million in matching funds from California and federal coffers to create a pharmacogenomics and toxicogenomics research epicenter that can supplement curricula from the university’s medical school and newly created school of pharmacy with information about these emerging fields.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.